US Bancorp DE boosted its holdings in Xencor, Inc. (NASDAQ:XNCR – Get Rating) by 324.9% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 939 shares of the biopharmaceutical company’s stock after buying an additional 718 shares during the quarter. US Bancorp DE’s holdings in Xencor were worth $26,000 at the end of the most recent reporting period.
Several other hedge funds have also added to or reduced their stakes in XNCR. State Street Corp raised its holdings in Xencor by 19.7% during the 1st quarter. State Street Corp now owns 2,968,901 shares of the biopharmaceutical company’s stock worth $79,210,000 after purchasing an additional 488,131 shares during the last quarter. Renaissance Technologies LLC acquired a new stake in shares of Xencor during the first quarter worth $6,267,000. Invesco Ltd. raised its stake in Xencor by 60.5% during the first quarter. Invesco Ltd. now owns 491,538 shares of the biopharmaceutical company’s stock worth $13,113,000 after buying an additional 185,290 shares during the last quarter. Tekla Capital Management LLC lifted its holdings in Xencor by 110.3% in the second quarter. Tekla Capital Management LLC now owns 236,996 shares of the biopharmaceutical company’s stock valued at $6,487,000 after buying an additional 124,323 shares during the period. Finally, Loomis Sayles & Co. L P boosted its position in Xencor by 6.7% during the first quarter. Loomis Sayles & Co. L P now owns 1,818,057 shares of the biopharmaceutical company’s stock valued at $48,506,000 after acquiring an additional 113,818 shares during the last quarter. 99.28% of the stock is currently owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
Several research firms have recently weighed in on XNCR. StockNews.com started coverage on Xencor in a research report on Wednesday, October 12th. They issued a “sell” rating for the company. Royal Bank of Canada dropped their price target on Xencor from $40.00 to $36.00 and set an “outperform” rating on the stock in a research note on Tuesday, November 8th. JPMorgan Chase & Co. began coverage on shares of Xencor in a research report on Wednesday, September 21st. They set an “overweight” rating and a $37.00 price objective for the company. Canaccord Genuity Group lowered their price objective on shares of Xencor from $50.00 to $48.00 in a research note on Wednesday. Finally, Raymond James raised shares of Xencor from an “outperform” rating to a “strong-buy” rating and set a $58.00 target price on the stock in a research note on Thursday, October 13th. One research analyst has rated the stock with a sell rating, eight have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Xencor presently has an average rating of “Moderate Buy” and an average target price of $48.89.
Xencor Price Performance
Xencor Company Profile
Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.
- Get a free copy of the StockNews.com research report on Xencor (XNCR)
- MarketBeat: Week in Review 11/7 – 11/11
- Oil Is a Compelling Reason The Sell-Off In Stocks Isn’t Over
- Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?
- Six Flags is a Ride You Don’t Want to Get Stuck On
- Vision Hydrogen, Now Vision Energy, Puts Hopes In Stock Split
Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.